The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
Pharmaceutical giants like Novo Nordisk and Eli Lilly are transforming GLP-1 drugs into everyday consumer products, introducing oral versions and emphasizing cash-pay models. This shift, driven by telehealth and apps, aims to make weight loss as accessible as online shopping, while experts raise concerns about medical oversight.
Tirzepatide, known as Mounjaro or Zepbound, serves as a medication for diabetes and weight management but comes with a steep price. Without insurance, monthly expenses can range from $500 to $1,900, varying by type and purchase location. This piece explores pricing details, insurance coverage, cost-saving strategies, and budget-friendly substitutes.
Weight loss medications such as Wegovy and Zepbound are set to become more accessible and affordable, moving beyond high costs and weekly shots. New pill forms offer alternatives for those avoiding injections, with significant developments in GLP-1 treatments expected. Advances in pricing and access programs aim to broaden availability for patients.
The year 2025 has seen a relentless barrage of ads promoting GLP-1 medications for weight loss, often bypassing FDA approvals and focusing on cosmetic benefits. Despite regulations limiting their use to specific medical conditions, telehealth companies push compounded versions aggressively. This trend threatens to undermine the body positivity movement by exploiting insecurities for profit.
The landscape of GLP-1 medications for weight loss is shifting towards consumer-driven models, with pill versions offering flexibility and telehealth platforms making access easier. Industry experts envision daily routines incorporating these drugs alongside apps, while concerns arise about medical oversight and long-term effects. This evolution could expand the market significantly, driven by affordability and marketing.
In her early thirties, Aisling McCarthy battled severe pain from arthritis and fibromyalgia, leading to emotional eating and significant weight gain. After trying various diets without lasting success, she turned to Ozempic, which drastically improved her health and mobility. She warns against common errors like neglecting mental health, emphasizing gradual weaning to sustain results.
A recent JAMA study reveals that a significant number of older adults are ceasing GLP-1 medications within a year, driven by factors like high costs and adverse reactions. Experts emphasize the importance of personalized monitoring to mitigate side effects such as muscle loss. Understanding these reasons can help improve adherence to weight management treatments.
Media mogul Oprah Winfrey has openly discussed her use of GLP-1 drugs for shedding pounds, but she recently shared a surprising outcome: the end of her alcohol consumption. This change has revitalized her sense of vitality and openness, while offering insights into obesity and personal growth. She encourages others to embrace available options without self-blame.
New studies indicate that halting popular GLP-1 medications before or shortly after conception results in more substantial weight increases during pregnancy and elevated chances of serious issues for both mother and child. This comes amid rising usage of these drugs for weight management and diabetes control. Experts emphasize the need for further investigation into balancing pre-pregnancy advantages with post-discontinuation risks.
